Incannex Healthcare: Data opens path to treat anxiety

In March 2023, Incannex Healthcare released interim trial analysis from the first study of its kind into the safety and efficacy of psilocybin for treating generalized anxiety disorder (GAD).

In this video, chief scientific officer Dr Mark Bleackley and CEO Joel Latham discuss the Phase II Psi-GAD1 clinical trial, its results and implications with BBC broadcaster Vivienne Parry.

Incannex is an Australian dual-listed biotech company developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies. Target indications include GAD, the condition being studied in the trial discussed in this video, as well as obstructive sleep apnea, trauma and inflammatory conditions.